Spyre Therapeutics, Inc. (SYRE)
NASDAQ: SYRE · Real-Time Price · USD
15.22
-0.80 (-4.99%)
At close: Jun 27, 2025, 4:00 PM
15.22
0.00 (0.00%)
After-hours: Jun 27, 2025, 4:34 PM EDT
Spyre Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
65
Market Cap
918.58M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
SYRE News
- 9 days ago - Spyre Therapeutics: Positive Anti-TL1A Data Brings 2 Program Pathways Forward - Seeking Alpha
- 11 days ago - Spyre Therapeutics Announces Positive Interim Phase 1 Results for Two Next-Generation TL1A Antibody Programs, and Provides Clinical Development Updates Expected to Deliver 9 Phase 2 Readouts - PRNewsWire
- 11 days ago - Spyre Therapeutics to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trials for its SPY002 Program, its Novel Half-Life Extended Anti-TL1A Antibodies on June 17, 2025 - PRNewsWire
- 21 days ago - Spyre Therapeutics Announces Grants of Inducement Awards - PRNewsWire
- 4 weeks ago - Spyre Therapeutics to Participate in Upcoming June Investor Conferences - PRNewsWire
- 7 weeks ago - Spyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update - PRNewsWire
- 7 weeks ago - Spyre Therapeutics Announces Poster Presentations at Digestive Disease Week (DDW) 2025 Including Up to Eight months of Follow-up from an Ongoing Phase 1 Trial of SPY001 - PRNewsWire
- 3 months ago - Spyre Therapeutics Announces First Participant Dosed in Phase 1 Trial of SPY003, its Novel Half-life Extended IL-23 Antibody - PRNewsWire